MARKET

ACTU

ACTU

Actuate Therapeutics Inc
NASDAQ
0.3288
+0.0018
+0.55%
After Hours: 0.3223 -0.0065 -1.98% 19:59 11/06 EST
OPEN
0.3270
PREV CLOSE
0.3270
HIGH
0.3499
LOW
0.3006
VOLUME
518.07K
TURNOVER
--
52 WEEK HIGH
7.90
52 WEEK LOW
0.3006
MARKET CAP
18.08M
P/E (TTM)
-0.3698
1D
5D
1M
3M
1Y
5Y
1D
Actuate Advances Oral Elraglusib Toward 2027 Trial Following Positive Melanoma Data
NASDAQ · 4d ago
Actuate Therapeutics To Present New Clinical Data Of Oral Elraglusib At 38th EORTC-NCI-AACR Symposium On Molecular Targets And Cancer Therapeutics
Benzinga · 4d ago
Actuate Therapeutics receives notice of allowance for Elraglusib patent
TipRanks · 6d ago
Weekly Report: what happened at ACTU last week (1026-1030)?
Weekly Report · 6d ago
Actuate Therapeutics Completes Public Equity and Warrant Offering
TipRanks · 10/28 21:47
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 10/27 17:05
Nasdaq Gains Over 150 Points; Coca-Cola Posts Upbeat Earnings
Benzinga · 10/27 13:52
Actuate Therapeutics announces pricing of $11M public offering
TipRanks · 10/27 12:26
More
About ACTU
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). The Company is developing elraglusib, a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3b, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, which lead to tumor cell survival, growth, migration, and invasion. Its candidate products are Elraglusib Injection and Elraglusib Oral Tablet. Elraglusib is the lead drug in the portfolio and is being evaluated in a randomized Phase II trial in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Elraglusib is designed to act as a mediator of antitumor immunity through the inhibition of NF-kB and regulates multiple immune checkpoints and immune cell function.

Webull offers Actuate Therapeutics Inc stock information, including NASDAQ: ACTU real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACTU stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACTU stock methods without spending real money on the virtual paper trading platform.